Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Childhood Acute Lymphoblastic Leukemia
100%
Improved Outcomes
100%
Contemporary Therapy
100%
ETV6-RUNX1
100%
Overall Survival
33%
Event-free Survival
22%
Acute Lymphoblastic Leukemia
22%
Minimal Residual Disease
22%
Leukemia
11%
Adverse Events
11%
Risk-adapted Therapy
11%
Newly Diagnosed
11%
Low Risk
11%
Total Therapy
11%
L-asparaginase
11%
Prognostic Factors
11%
Leukemia Patients
11%
Precursor B-cell Acute Lymphoblastic Leukemia
11%
High-dose Methotrexate (HD-MTX)
11%
Drug Sensitivity
11%
Genetic Aberrations
11%
ETV6-RUNX1 Fusion
11%
Treatment Protocol
11%
Response Event
11%
Guided Therapy
11%
Clinical Features
11%
Treatment-based Classification
11%
Treatment Schema
11%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
100%
Overall Survival
60%
Minimal Residual Disease
40%
Event Free Survival
40%
Drug Megadose
20%
Prognostic Factor
20%
Leukemia
20%
Adverse Event
20%
Precursor
20%
Asparaginase
20%
Clinical Feature
20%
Methotrexate
20%
Treatment Classification
20%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
100%
Overall Survival
60%
Minimal Residual Disease
40%
Event Free Survival
40%
Adverse Event
20%
Leukemia
20%
Asparaginase
20%
Methotrexate
20%
Clinical Feature
20%
Biochemistry, Genetics and Molecular Biology
ETV6
100%
RUNX1
100%
Overall Survival
30%
Event Free Survival
20%
Genetics
10%
Precursor
10%
Drug Megadose
10%
Asparaginase
10%
Methotrexate
10%
Neuroscience
RUNX1
100%
ETV6
100%
Asparaginase
10%
Methotrexate
10%